Building the foundation for the Clinical FCM business
First written in FY2017. 4 of 8 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「May 2023: In Japan, we launched the Clinical Flow Cytometry System combining the Flow Cytometer XF-1600 and the Sample Preparation System PS-10, together with related products including antibody reagents.」
It reiterates the domestic launch of XF-1600, PS-10 and related products as part of the status of research and development activities. - FY2024-Q1AdvancedAnnual report
「① May 2023: In Japan, we launched the Clinical Flow Cytometry System combining the Flow Cytometer XF-1600 and the Sample Preparation System PS-10, together with related products including antibody reagents.」
Regarding the clinical FCM business, following overseas launches, it launched XF-1600, PS-10 and related products in Japan, making end-to-end automation from sample preparation through the acquisition of measurement results concrete in the domestic market. - FY2021-Q1AdvancedAnnual report
「June 2020: We launched the Flow Cytometer XF-1600 in North America. Used as a flow cytometer system together with the Sample Preparation System PS-10, launched in August 2019 to automate sample preparation, antibody reagents and data-analysis software, it enables automation of the entire workflow for FCM testing, from sample preparation through the acquisition of measurement results.」
It made the overall automation of FCM testing, from sample preparation through the acquisition of results, concrete by launching Flow Cytometer XF-1600 in North America and combining it with PS-10, antibody reagents and data-analysis software. - FY2020AdvancedAnnual report
「In the FCM business, we will accelerate the development and market introduction of instruments and reagents for the early commercialization of clinical FCM, while promoting the introduction of the WHO-prequalified CyFlow™ Counter System in countries and regions with limited medical resources.」
In addition to developing clinical FCM instruments and reagents, it added a policy of introducing the WHO-prequalified CyFlow™ Counter System in regions with limited medical resources. - FY2020-Q3RestatedAnnual report
「August 2019: We launched the Sample Preparation System PS-10 in the North American market for clinical FCM testing, which uses flow cytometry (FCM) for detailed analyses in the diagnosis of leukemia, malignant lymphoma and other conditions. The system automatically performs sample preparation.」
It reiterates the launch of PS-10 in the North American market and the automation of sample preparation for clinical FCM testing. - FY2020-Q2AdvancedAnnual report
「In the clinical FCM testing market, which uses flow cytometry for detailed analyses in the diagnosis of leukemia, malignant lymphoma and other conditions, we launched the Sample Preparation System PS-10 in North America in August 2019. The system automates the complex sample-preparation processes required for FCM testing, delivers an efficient workflow and contributes to the standardization of FCM testing. With a view to future global expansion, we are also pursuing regulatory approvals for flow cytometers, the instruments used for measurement, in countries around the world.」
Regarding the clinical FCM business, it states that PS-10, which automates sample preparation, was launched in North America in August 2019 to improve the efficiency and standardization of FCM testing. It also describes activities to obtain regulatory approvals for measuring instruments in each country. - FY2018RestatedAnnual report
「To commercialize clinical FCM at an early stage, we will accelerate the development and market introduction of instruments and reagents. We will also strengthen sales promotion in the research and industrial fields.」
It reiterates the development and market introduction of clinical FCM instruments and reagents and strengthened sales promotion in the research and industrial fields. - FY2017First statedAnnual report
「To commercialize clinical FCM at an early stage, we will accelerate the development and market introduction of instruments and reagents. We will also strengthen sales promotion in the research and industrial fields.」
A new initiative to build the foundation for the business by combining the development and market introduction of clinical FCM instruments and reagents with sales promotion in the research and industrial fields.